These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32564404)

  • 1. Managing the significant interaction between XR tacrolimus and fluconazole in kidney transplant recipients.
    Lange NW; Hedvat J; Tsapepas DS; Salerno DM
    Clin Transplant; 2020 Aug; 34(8):e14001. PubMed ID: 32564404
    [No Abstract]   [Full Text] [Related]  

  • 2. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
    Ulsh PJ; Yang HC; Holman MJ; Ahsan N
    J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
    Solomon S; Colovai A; Del Rio M; Hayde N
    Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-center experience with nirmatrelvir/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression.
    Mecadon K; Arvanitis P; Farmakiotis D; Rogers R
    Clin Transplant; 2022 Aug; 36(8):e14752. PubMed ID: 35713302
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.
    Webster A; Woodroffe RC; Taylor RS; Chapman JR; Craig JC
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003961. PubMed ID: 16235347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colchicine levels in chronic kidney diseases and kidney transplant recipients using tacrolimus.
    Amanova A; Kendi Celebi Z; Bakar F; Caglayan MG; Keven K
    Clin Transplant; 2014 Oct; 28(10):1177-83. PubMed ID: 25125128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
    Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing Tacrolimus Levels to Improve Cognitive Function in Kidney Transplant Recipients.
    Bigotte Vieira M
    Kidney360; 2024 Jul; 5(7):936-937. PubMed ID: 39052471
    [No Abstract]   [Full Text] [Related]  

  • 11. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of patiromer use with tacrolimus in kidney transplant recipients.
    Rattanavich R; Malone AF; Alhamad T
    Transpl Int; 2019 Jan; 32(1):110-111. PubMed ID: 30444015
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
    Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
    Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients.
    Hu RH; Lee PH; Tsai MK
    Transplant Proc; 2000 Nov; 32(7):1689-92. PubMed ID: 11119894
    [No Abstract]   [Full Text] [Related]  

  • 15. Advagraf® with or without an induction therapy for de novo kidney-transplant recipients.
    Noble J; Jouve T; Rostaing L; Malvezzi P
    Expert Rev Clin Immunol; 2018 Jun; 14(6):461-467. PubMed ID: 29757021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients.
    Dudley CR;
    Transplant Proc; 2001; 33(1-2):1034-5. PubMed ID: 11267179
    [No Abstract]   [Full Text] [Related]  

  • 17. Tacrolimus in pediatric renal transplantation: a review.
    Shapiro R
    Pediatr Transplant; 1998 Nov; 2(4):270-6. PubMed ID: 10084728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus once-daily formulation in the prophylaxis of transplant rejection in renal or liver allograft recipients: a viewpoint by Sander Florman.
    Florman S
    Drugs; 2007; 67(13):1944. PubMed ID: 17722964
    [No Abstract]   [Full Text] [Related]  

  • 19. Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients.
    Handisurya A; Kerscher C; Tura A; Herkner H; Payer BA; Mandorfer M; Werzowa J; Winnicki W; Reiberger T; Kautzky-Willer A; Pacini G; Säemann M; Schmidt A
    PLoS One; 2016; 11(1):e0145319. PubMed ID: 26735686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter trial of FK506 as rescue therapy for renal transplant recipients in Taiwan.
    Shu KH; Cheng CH; Wu MJ; Lian JD; Huang CC; Chu SH; Chiang YJ; Lai MK; Lee PH
    Transplant Proc; 1998 Nov; 30(7):3584-6. PubMed ID: 9838570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.